ADPT Adaptive Biotechnologies
- 4.000
- +0.110+2.83%
- 3.890
- -0.110-2.75%
Adaptive Biotechnologies News
Insiders At Adaptive Biotechnologies Sold US$664k In Stock, Alluding To Potential Weakness
Quite a few Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insiders sold their shares over the past year, which may be a cause for concern. When analyzing insider transactions, it is usually
Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024
SEATTLE, July 11, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical
Cathie Wood-Led Ark Invest Scoops Up $5.16M Worth Of Palantir Shares Amid Raging AI Fervor
On Monday, Cathie Wood-led Ark Invest made a notable investment in Palantir Technologies Inc (NYSE:PLTR), a move that comes as the AI sector gains momentum.
Express News | Adaptive Biotechnologies Says Its Next-generation Sequencing-based ClonoSEQ Test For Measurable Residual Disease Assessment Will Be Included In Several Oral And Poster Presentations At American Society Of Clinical Oncology Annual Meeting
Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment With ClonoSEQ To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
SEATTLE, May 31, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical
Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
SEATTLE, May 29, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical
Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 50% Higher
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) shareholders are no doubt pleased to see that the share price has bounced 50% in the last month, although it is still struggling to make up recently
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Warby Parker (WRBY) and Adaptive Biotechnologies (ADPT)
Why Adaptive Biotechnologies Topped the Market Today
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q1 2024 Earnings Call Transcript
Earnings Call Summary | Adaptive Biotechnologies(ADPT.US) Q1 2024 Earnings Conference
The following is a summary of the Adaptive Biotechnologies Corporation (ADPT) Q1 2024 Earnings Call Transcript:Financial Performance:Adaptive Biotechnologies reported Q1 2024 revenue of $41.99 million
Express News | Adaptive Biotechnologies Corp : Btig Raises Target Price to $6 From $5
Analysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (ADPT), Veracyte (VCYT) and Nevro Corp (NVRO)
Analysts Offer Insights on Healthcare Companies: Clover Health Investments (CLOV), Cogent Biosciences (COGT) and Adaptive Biotechnologies (ADPT)
Adaptive Biotechnologies Corp (ADPT) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
Compared to Estimates, Adaptive Biotechnologies (ADPT) Q1 Earnings: A Look at Key Metrics
Adaptive Biotechnologies Q1 Loss Decreases, Beats Estimates
Adaptive Biotechnologies | 10-Q: Quarterly report
Earnings Flash (ADPT) ADAPTIVE BIOTECHNOLOGIES Reports Q1 Revenue $41.9M, Vs. Street Est of $38.8M
04:36 PM EDT, 05/07/2024 (MT Newswires) -- Earnings Flash (ADPT) ADAPTIVE BIOTECHNOLOGIES Reports Q1 Revenue $41.9M, vs. Street Est of $38.8M
Express News | Adaptive Biotechnologies Corp: Expect Full Year Total Company Operating Expenses, Including Cost of Revenue, to Be Between $350 Mln and $360 Mln
Analysis
Price Target
No Data
